News stories about T2 Biosystems (NASDAQ:TTOO) have been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. T2 Biosystems earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 47.0234137405991 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
- United Community Banks, Inc. (UCBI) Reaches $30.86 52-Week High; Tiger Management Has Boosted By $1.03 … – Hill Country Times (hillcountrytimes.com)
- T2 Biosystems, Inc. (TTOO) stock recent close stands at $5.42 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Analysts’ Recommendation in Spotlight: T2 Biosystems, Inc. (NASDAQ: TTOO) – The Investor Guide (wallstreetnews24.com)
- Reviewing STAAR Surgical (STAA) & T2 Biosystems (TTOO) (americanbankingnews.com)
Shares of T2 Biosystems (NASDAQ TTOO) traded down $0.22 during midday trading on Monday, hitting $5.20. 250,800 shares of the stock traded hands, compared to its average volume of 403,378. The company has a debt-to-equity ratio of 2.25, a current ratio of 5.40 and a quick ratio of 5.28. The stock has a market cap of $186.29, a PE ratio of -2.74 and a beta of 1.48. T2 Biosystems has a 52-week low of $2.50 and a 52-week high of $6.99.
Several equities analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of T2 Biosystems from a “buy” rating to a “hold” rating in a research report on Saturday, January 6th. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of T2 Biosystems in a research note on Friday, November 3rd. Finally, Canaccord Genuity restated a “buy” rating and set a $6.00 target price on shares of T2 Biosystems in a research note on Monday, October 30th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. T2 Biosystems presently has a consensus rating of “Hold” and a consensus target price of $6.54.
ILLEGAL ACTIVITY NOTICE: “T2 Biosystems (NASDAQ:TTOO) Receives Daily News Sentiment Rating of 0.10” was published by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/t2-biosystems-ttoo-earning-somewhat-positive-press-coverage-study-shows/1818884.html.
About T2 Biosystems
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.